Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
The US Food and Drug Administration has approved a new nasal spray for depression treatment. Known as Spravato and ...
The U.S. Food and Drug Administration (FDA) approved the antidepressant nasal spray Spravato as a standalone treatment for depression in adults.
The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...
The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.
CIII nasal spray, marking the first monotherapy to be approved for adults with treatment-resistant depression (TRD).
The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...
The accelerating sales growth of Johnson & Johnson's Spravato could go up yet another gear after the FDA approved a third ...
(HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at ...
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of MDD in those who have not responded to at least two oral antidepressants. Hundreds of ...
Health and Me on MSN6d
FDA Approves ‘Spravato’ Nasal Spray As A Standalone Depression TreatmentWe have made great strides in the medical community, with people having access to life-saving physical drugs as well as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback